2021
The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Journal Of Clinical Oncology 2021, 39: 247-247. DOI: 10.1200/jco.2021.39.3_suppl.247.Peer-Reviewed Original ResearchFTD/TPI treatmentSafety profileAdverse eventsSafety of FTD/TPIGastroesophageal junction cancerThird-line chemotherapySecond-line treatmentPost hoc analysisHematologic toxicityOS benefitChemotherapy regimensJunction cancerSurvival benefitEfficacy benefitsFTD/TPIRamucirumabTagging trialsPlaceboPaclitaxelPrior treatmentAssociated with benefitsHoc analysisInfluence outcomesChemotherapySubgroup A
2020
The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center.
Wong R, Wu J, Leen A, Tey G, Asokumaran Y, Chan G, Siddappan C, Jeyasekharan A, Chee C, Yong W, Ngiam K, Sundar R. The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Journal Of Clinical Oncology 2020, 38: e16623-e16623. DOI: 10.1200/jco.2020.38.15_suppl.e16623.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaEra of immunotherapySequence of therapySystemic therapyOverall survivalHCC patientsClinical outcomesManagement of advanced hepatocellular carcinomaTreated with first-line immunotherapyTreatment of advanced hepatocellular carcinomaFirst-line immunotherapyFirst-line TKIsSecond-line immunotherapySecond-line TKIsLoco-regional therapiesProgression-free survivalSecond-line therapySecond-line treatmentPillar of treatmentChild-Pugh scoreMinority of patientsSecond-lineFirst-lineMedian ageTargeted therapy